ZA201702545B - Neuroactive compounds and methods of use thereof - Google Patents
Neuroactive compounds and methods of use thereofInfo
- Publication number
- ZA201702545B ZA201702545B ZA2017/02545A ZA201702545A ZA201702545B ZA 201702545 B ZA201702545 B ZA 201702545B ZA 2017/02545 A ZA2017/02545 A ZA 2017/02545A ZA 201702545 A ZA201702545 A ZA 201702545A ZA 201702545 B ZA201702545 B ZA 201702545B
- Authority
- ZA
- South Africa
- Prior art keywords
- methods
- neuroactive compounds
- neuroactive
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462060932P | 2014-10-07 | 2014-10-07 | |
| PCT/US2015/054551 WO2016057713A1 (en) | 2014-10-07 | 2015-10-07 | Neuroactive compounds and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201702545B true ZA201702545B (en) | 2019-06-26 |
Family
ID=55653736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2017/02545A ZA201702545B (en) | 2014-10-07 | 2017-04-10 | Neuroactive compounds and methods of use thereof |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20170304321A1 (https=) |
| EP (1) | EP3204011A4 (https=) |
| JP (3) | JP2017530982A (https=) |
| KR (1) | KR20170065637A (https=) |
| CN (2) | CN107405352A (https=) |
| AU (2) | AU2015330906A1 (https=) |
| BR (1) | BR112017007053A2 (https=) |
| CA (1) | CA2963938C (https=) |
| IL (2) | IL292465B2 (https=) |
| MX (2) | MX388694B (https=) |
| MY (1) | MY202135A (https=) |
| PE (1) | PE20170907A1 (https=) |
| PH (1) | PH12017500639A1 (https=) |
| RU (1) | RU2764702C2 (https=) |
| SG (2) | SG11201702799UA (https=) |
| WO (1) | WO2016057713A1 (https=) |
| ZA (1) | ZA201702545B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20230747T1 (hr) | 2011-09-08 | 2024-01-05 | Sage Therapeutics, Inc. | Neuroaktivni steroidi, pripravci i njihova uporaba |
| SMT201800657T1 (it) | 2013-03-13 | 2019-01-11 | Sage Therapeutics Inc | Steroidi neuroattivi e loro metodi di utilizzo |
| CN105073728A (zh) | 2013-03-15 | 2015-11-18 | 全球血液疗法股份有限公司 | 化合物及其用于调节血红蛋白的用途 |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| PL3639828T3 (pl) | 2013-12-24 | 2022-05-02 | Virginia Commonwealth University | Zastosowanie utlenowanych siarczanów cholesterolu (ocs) w leczeniu ostrej niewydolności wątroby |
| WO2015195967A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| MX382122B (es) | 2015-07-06 | 2025-03-13 | Sage Therapeutics Inc | Oxiesteroles y metodos de uso de los mismos. |
| AU2016289965B2 (en) | 2015-07-06 | 2021-09-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| PL3319611T3 (pl) | 2015-07-06 | 2021-07-12 | Sage Therapeutics, Inc. | Oksysterole i sposoby ich stosowania |
| EP3436022B1 (en) | 2016-04-01 | 2022-03-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| US10752653B2 (en) | 2016-05-06 | 2020-08-25 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| WO2018009867A1 (en) | 2016-07-07 | 2018-01-11 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| EP3494125B1 (en) * | 2016-08-02 | 2022-06-22 | Virginia Commonwealth University | Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide |
| PT3519422T (pt) | 2016-09-30 | 2022-12-05 | Sage Therapeutics Inc | Oxisteróis substituídos em c7 e métodos como moduladores nmda |
| CA3041088C (en) * | 2016-10-18 | 2024-05-21 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| DK4105223T3 (da) | 2016-10-18 | 2025-07-07 | Sage Therapeutics Inc | Oxysteroler og fremgangsmåder til anvendelse deraf |
| EP3335730A1 (en) * | 2016-12-15 | 2018-06-20 | Fundació Institut de Recerca Biomédica de Bellvitge (IDIBELL) | Compounds for treating x-linked adrenoleukodystrophy |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| WO2006037016A2 (en) * | 2004-09-27 | 2006-04-06 | The Regents Of The University Of California | Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| GB0712494D0 (en) * | 2007-06-27 | 2007-08-08 | Isis Innovation | Substrate reduction therapy |
| EP2207542A2 (en) * | 2007-11-06 | 2010-07-21 | N.V. Organon | A method of hormone suppression in humans |
| NZ589764A (en) * | 2008-05-09 | 2012-10-26 | Univ Emory | NMDA receptor antagonists for the treatment of neuropsychiatric disorders |
| WO2010065709A2 (en) * | 2008-12-03 | 2010-06-10 | Amin Khan | Hydroxamic acid derivatives, preparation and therapeutic uses thereof |
| US20110319416A1 (en) * | 2009-01-28 | 2011-12-29 | Emory University | Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions |
| WO2011028794A2 (en) * | 2009-09-01 | 2011-03-10 | Lazarus Therapeutics, Inc. | Treatment of huntington's disease with cycloserine and an nmda receptor antagonist |
| KR101692275B1 (ko) * | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| US20120035156A1 (en) * | 2010-08-09 | 2012-02-09 | Daniela Alberati | Combination of glyt1 compound with antipsychotics |
| HRP20230747T1 (hr) * | 2011-09-08 | 2024-01-05 | Sage Therapeutics, Inc. | Neuroaktivni steroidi, pripravci i njihova uporaba |
| WO2013163455A2 (en) * | 2012-04-25 | 2013-10-31 | The Regents Of The University Of California | A drug screening platform for rett syndrome |
| WO2014025942A1 (en) * | 2012-08-09 | 2014-02-13 | Emory University | Nmda receptor modulators and uses related thereto |
| KR20150110787A (ko) * | 2013-01-29 | 2015-10-02 | 노렉스, 인크. | 스피로-락탐 nmda 수용체 조절인자 및 그의 용도 |
| CN105164161A (zh) * | 2013-03-13 | 2015-12-16 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物、及其用途 |
| SMT201800657T1 (it) | 2013-03-13 | 2019-01-11 | Sage Therapeutics Inc | Steroidi neuroattivi e loro metodi di utilizzo |
| WO2015195967A1 (en) * | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| US10238664B2 (en) * | 2014-07-09 | 2019-03-26 | Duke University | Compositions and methods for the repair of myelin |
| AU2016289965B2 (en) * | 2015-07-06 | 2021-09-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
-
2015
- 2015-10-07 SG SG11201702799UA patent/SG11201702799UA/en unknown
- 2015-10-07 BR BR112017007053A patent/BR112017007053A2/pt not_active Application Discontinuation
- 2015-10-07 PE PE2017000579A patent/PE20170907A1/es unknown
- 2015-10-07 RU RU2017115849A patent/RU2764702C2/ru active
- 2015-10-07 MY MYPI2017000507A patent/MY202135A/en unknown
- 2015-10-07 SG SG10202011773UA patent/SG10202011773UA/en unknown
- 2015-10-07 KR KR1020177012221A patent/KR20170065637A/ko not_active Ceased
- 2015-10-07 EP EP15849514.3A patent/EP3204011A4/en active Pending
- 2015-10-07 CN CN201580063540.7A patent/CN107405352A/zh active Pending
- 2015-10-07 WO PCT/US2015/054551 patent/WO2016057713A1/en not_active Ceased
- 2015-10-07 CA CA2963938A patent/CA2963938C/en active Active
- 2015-10-07 AU AU2015330906A patent/AU2015330906A1/en not_active Abandoned
- 2015-10-07 US US15/517,886 patent/US20170304321A1/en not_active Abandoned
- 2015-10-07 MX MX2017004684A patent/MX388694B/es unknown
- 2015-10-07 JP JP2017518329A patent/JP2017530982A/ja not_active Withdrawn
- 2015-10-07 CN CN202011059273.5A patent/CN112121171A/zh active Pending
- 2015-10-07 IL IL292465A patent/IL292465B2/en unknown
-
2017
- 2017-04-02 IL IL251505A patent/IL251505B/en unknown
- 2017-04-06 PH PH12017500639A patent/PH12017500639A1/en unknown
- 2017-04-07 MX MX2021011939A patent/MX2021011939A/es unknown
- 2017-04-10 ZA ZA2017/02545A patent/ZA201702545B/en unknown
-
2020
- 2020-09-07 JP JP2020149725A patent/JP2020196759A/ja not_active Withdrawn
-
2021
- 2021-02-04 AU AU2021200721A patent/AU2021200721B2/en active Active
-
2022
- 2022-01-05 JP JP2022000454A patent/JP2022033285A/ja active Pending
- 2022-09-19 US US17/947,844 patent/US20230218638A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276946A (en) | Antiproliferative compounds and methods of use | |
| ZA201702545B (en) | Neuroactive compounds and methods of use thereof | |
| IL250415B (en) | Antibodies against pd-l and methods of using them | |
| PL3218005T3 (pl) | Związki oddziałujące z glikanami i sposoby ich zastosowania | |
| SG11201803213XA (en) | Glycan-interacting compounds and methods of use | |
| PL3089971T3 (pl) | Związki i sposoby ich zastosowania | |
| GB201418350D0 (en) | Dispenser and methods of use thereof | |
| HUE056172T2 (hu) | Szelenoorganikus vegyületeket tartalmazó készítmények és eljárások alkalmazásukra | |
| IL248529A0 (en) | Palladianolide pyridine compounds and methods of use | |
| IL253234A0 (en) | Methods for transdifferentiation and methods to use them | |
| ZA201606450B (en) | Compounds and their methods of use | |
| GB201403697D0 (en) | Compounds and methods of use | |
| HK1240856A1 (en) | Neuroactive compounds and methods of use thereof | |
| HK1228198A1 (en) | Compounds and their methods of use | |
| GB201416797D0 (en) | Contianer and method of use thereof |